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The gut microbiota interact with innate immune cells and play an important role in 
shaping the immune system.  Many factors may influence the composition of the 
microbiota such as mode of birth, diet, infections and medication including antibiotics.  
In diseases with a multifactorial etiology, like type 1 diabetes, manipulation and 
alterations of the microbiota in animal models has been shown to influence the 
incidence and onset of disease.  The microbiota are an important part of the internal 
environment and understanding how these bacteria interact with the innate immune 
cells to generate immune tolerance may open up opportunities for development of new 
therapeutic strategies.  In this review, we discuss recent findings in relation to the 

























































31. Gut microbiota and type 1 diabetes
Type 1 diabetes (T1D) is a T cell-mediated autoimmune metabolic disease which is 
commonly seen in children and young adults (1) although it can also present in older 
adults.  The insulin-producing beta cells of the pancreatic islets are damaged and 
destroyed by activated autoreactive T cells resulting in disordered blood glucose 
regulation (2).  This destruction is the result of a complex interaction between genetic 
susceptibility genes and environmental factors (3, 4). Genetic screening has shown that 
certain major histocompatibility complex (MHC) class II genes, also called human 
leukocyte antigen (HLA) genes, DQA1*0301 (DQ2), DQB1*0302 (DQ8), DRB1*DR301 
(DR3) and a number of DR4 alleles are associated with susceptibility to T1D in patients (5, 
6).  However, only a small portion of individuals carrying those alleles will develop T1D 
(7).  Yet, a sharp rise of T1D incidence has been seen in recent years (8) in a time frame 
that is not sufficient for genetic change, indicating that environmental factors may play 
a crucial role in diabetes development (9).  Prenatal influence, viral infections, dietary 
factors in the young as well as “hygiene” can all affect the disease onset (10).  More 
recently, several studies have shown commensal microbiota to be connected with the 
development of this autoimmune disease (11).  Although triggering factors for T1D 
have not yet been clearly identified, the gut microbiota are believed to play an 
important role in the development of the disease (12, 13).
The gut microbiota are associated with the development of several diseases including 

























































4(16), allergic diseases (17), disorders in the central nervous system (18), and especially, 
autoimmune diseases (19-22).  We, and others, have recently reported that alteration 
of gut microbiota by pharmacological means can protect from or accelerate T1D 
development in non-obese diabetic (NOD) mice (23-27), a well established animal model 
for T1D research (28).
We were among the first to demonstrate that the gut microbiota shape the NOD mouse 
innate immune system (11).  MyD88 is a central adaptor in most innate immune Toll-
like receptor signaling pathways and MyD88-deficient NOD mice do not develop 
autoimmune diabetes in a clean, but not sterile, housing environment; however, germ-
free MyD88-deficient mice develop full-blown diabetes (11).  This indicates that 
commensal bacteria, especially gut bacteria play a very important role in triggering the 
autoimmune disease.  When a defined microbial mixture was introduced orally into 
the germ-free MyD88-deficient mice, diabetes development in these mice was 
attenuated (11).  Similar results were later observed in different mouse models of 
human diseases including Celiac Disease (29), obesity/type 2 diabetes (30), and 
autoimmune uveitis (31).
There are 10-fold more microorganisms residing in the gut than the total number of 
human cells (32), and they protect the host from infection by various pathogens (33).  
The main roles of gut bacteria are to aid in nutrition derived from the diet and to 
generate energy.  A healthy microbiota composition helps to keep the gut epithelia 

























































5epithelia and the bacteria promotes the development of a normal immune system (36, 
37).  Several reports have demonstrated that colonization by some specific bacteria in 
the gut can protect mice from developing type 1 diabetes; these bacteria include SFB 
(Segmented Filamentous Bacteria) (38), Lactobacillus johnsonii N6.2 (39), as well as 
some Streptococcal species (40), and glycoprotein extracts from Klebsiella pneumoniae 
(41).
2. Modification of the gut microbiota
Although controversial, germ-free mice (11, 42-44) may have accelerated T1D. 
Conversely, there has been speculation that gut bacteria may trigger T1D development 
in genetically susceptible humans (45) and mouse models of T1D (46).  One possible 
means by which this could occur could be transfer of metabolites or cell components of 
the bacteria through a “leaky” gut wall and uptake by antigen presenting cells, 
processing and presentation of the antigen to activate T cells (47).  Tight junctions 
represent the major barrier within the paracellular pathway between intestinal 
epithelial cells.  Alterations in intestinal permeability allow access of bacterial toxin 
(45), infectious agents and dietary antigens from the lumen to mucosal immune 
elements (48, 49).  Another possible mechanism is some bacterial product(s) share the 
molecular homology with islet autoantigen(s) and the islet beta cells are attacked by the 
immune cells that are reactive to the bactierial antigens (46).

























































651).  Animal model studies have also shown that alteration of gut microbiota early in 
life, and gut permeability are important in shaping the host immune system (25, 52, 53), 
especially at the prenatal or neonatal stages.
Efforts have been made to investigate which bacteria in the gut may be beneficial or 
harmful in the development of T1D (45, 46, 54-57).  Researchers have studied altered 
gut microbiota in experimental mice after treating with a combination of 4 antibiotics, 
including Ampicillin, Metronidazole, Neomycin and Vancomycin (58).  Although there 
are studies using germ-free (GF) mice to test whether one or more species of bacteria 
introduced into the mice has an impact on diabetes development (42, 59), which species 
are probiotic and which are detrimental have not been conclusively determined, as most 
of the bacteria in the gut are non-culturable.
Other studies have been conducted using vancomycin, a specific gram-positive bacterial 
inhibitor, to modify the gut bacteria.  Antibiotic intervention during the prenatal period 
revealed an acceleration of diabetes onset (27, 60), whereas NOD mice receiving 
vancomycin from birth onwards gave the opposite result (52).  Recently, Brown and 
colleagues showed that using Neomycin and Vancomycin to treat NOD mouse pups from 
the neonatal period for their lifetime (61) accelerated diabetes development.  These 
studies indicated that the time at which antibiotic treatment is commenced is crucial 
and that treating the mothers may be a way of having an effect while avoiding direct 
administration of the antibiotics to the pups.  Many of these studies used an approach 

























































7occurs in humans.  Thus, the advantage of studying short-term treatment makes the 
studies in animals closer to humans (25, 27).  In addition, human studies have shown 
that approximately 30% of pregnant women in the USA have had a short-course of 
antibiotic medication during their pregnancy (62) and the number could be higher in 
other countries.  It should be noted that long-term antibiotic treatment could cause 
resistant bacteria to propagate in the gut (63).
3. Protective bacteria that arise from pharmacological alteration of gut microbiota in 
early life.
The colonization of gut microbiota is strongly influenced by microbial exposure at birth 
(64).  When antibiotic treatment is used to study the effect of gut microbiota on 
disease, it is clear that the timing of administration, duration of treatment, as well as the 
type of antibiotic used must be taken into account.  We have published a study 
showing that Neomycin/Polymyxin B/Streptomycin- treated NOD mice were protected 
from T1D development (25).  This protection was more significant when mice were 

















































































Figure 1: Maternal antibiotic treatment protects offspring from diabetes development in 
NOD mice.  Antibiotic treatment (3 week) starting at different times of life led to a 
different phenotype of T1D development. NPS (Neomycin/Polymyxin B/Streptomycin); 
NPS/preg (NOD offspring from mothers treated with NPS during pregnancy); NPS/born 
(NOD treated with NPS from birth to weaning); NPS/wean (NOD treated with NPS 
immediately after weaning).  The change in diabetes incidence was dependent on the 
time of antibiotic treatment.
It is clear that the earlier the NOD mice received the antibiotics, the better the 
protection from diabetes development.  In our study, NOD mice treated with NPS at 
different time points early in life delayed and overall reduced T1D onset.  When 
pregnant mothers were treated with antibiotics, the offspring were most protected 
from diabetes, while mice receiving antibiotics from birth or weaning were also 
protected from disease development although this was not statistically significant.  
Here, not only did the NPS treatment generate a gut bacterial composition that was 

























































9inducing the effects.  Overall, these studies suggest that gut microbiota in very early 
life (prenatal or neonatal) may have the most positive impact on the host immune 
system.  Other studies have demonstrated that microbial exposure during early life is 
important for development and maintenance of the immune system and germ-free mice 
are more susceptible to developing T1D (42, 43).
Considering which bacteria have protective effects in relation to diabetes development, 
we have observed that the Gram-positive Firmucutes Lachnospiraceae and 
Coriobacteriaceae significantly increased in prenatally NPS treated mice (25).  Several 
studies in mice and human case reports indicated that, in both BioBreeding Diabetes-
Prone rats (65-67) and diabetic children (68, 69), decreased Bacteroidetes, together with 
an increase in other Gram-positive Firmicutes such as Lactobacillus, Bifidobacterium, 
were found, compared to BioBreeding Diabetes-Resistant rats and healthy children, 
respectively.
SFB (Segmented Filamentous Bacteria) are a group of bacteria within the Genus 
Candidatus Arthromitus which belongs to the Phylum of Firmicutes, Class of Clostridia 
and Family of Lachnospiraceae(70).  SFB were found to induce intestinal Th17 cells in 
Lamina Propria (LP) (71) and there are reports showing that colonization of the gut of 
NOD mice with SFB can induce a substantial population of Th17 cells in the LP and 
protect the female NOD mice from diabetes development (38).  However, we did not 
find that SFB conferred diabetes protection in NOD mice (27).  A study by Yurkovetskiy 


























































development; however, SFB reduced T1D development in male GF NOD mice after 
colonization with other gut bacteria (72).  Since SFB are a group of bacteria, genomic 
sequencing results from several SFB strains have shown that they are different from 
each other (73-76).  It is, thereofre, conceivable that different strains may have 
different biological effects.  Nevertheless, it is still important to study the role of SFB in 
mice because these gram-positive, anaerobic, commensal bacteria are capable of 
inducing the postnatal maturation of homeostatic innate and adaptive immune 
responses in the gut.  A recent publication also showed that not only can colonization 
with SFB induce IL-17A but CXCR2-dependent recruitment of neutrophils in the gut also 
occurs (77).
4. Shaping the immune system via alterations in gut bacteria
How does alteration of the gut bacteria lead to protection from diseases like type 1 
diabetes?  There are a number of proposed mechanisms which are associated with 
genetics, gut microbiota (related to antibiotic usage, mode of delivery, diet) and 
infection in animal models and humans (78, 79).  Our recent studies indicate that 
protection can be mediated by tolerogenic antigne presenting cells (APCs) originating in 
the gut associated lymphoid tissue (GALT), which have reduced ability to stimulate 


























































Figure 2: How do antibiotics affect pancreatic beta cell autoimmunity: gut microbiota 
composition is altered after antibiotic (NPS) treatment and antigen presenting cells 
exposed to the altered bacteria in the gut display impaired antigen presenting ability to 
CD8 T cells, which in turn alleviate insulitis in the pancreas and protect the host from 
diabetes development.
In supporting the mechanism of tolerogenic APCs as a result of altered gut microbiota 
due to antibiotic usage, Umenai and coauthors showed hyporesponsiveness of 
macrophages, a potent subset of APCs, in response to LPS stimulation in mice after 
Streptomycin treatment (80).  Similarly, a recent study demonstrated that dendritic 
cells became hyporesponsive to LPS stimulation and reduced inflammatory cytokine 
production upon exposure to the gut bacterium Lactobacillus reuteri (81).  Dolpady and 
co-authors reported that administration of a mixture of Bifidobacteriaceae, 
Lactobacillaceae and Streptococcus in 4-wk old mice promoted tolerogenic CD103+ 
dendritic cells and reduced Th1 and Th17 cells in mucosal and PLN sites (82).  Thus, 


























































affect APCs lead to acceleration of or protection from diabetes development.  The 
changes in APC function could be the result of direct contact between APCs and gut 
microbiota in the gut or indirect contact, mediated by metabolites from altered gut 
microbiota.  Due to the immature nature of gut barrier and the changing, maturing 
community of gut microbiota in early-life, timing becomes critical.
Reduction in regulatory T cell markers have also been postulated as a mechanism for 
protection of NOD mice after treating with a mixture of antibiotics – metronidazole, 
streptomycin and polymyxin prenatally (53, 60).  These studies demonstrated that the 
changes in the immune system occurred when antibiotic treatment was given prenatally, 
a particularly important time for immune system development.  Livanos and coauthors 
reported recently that NOD mice receiving antibiotics (penicillin V) from lactation until 
the age of 40 days had earlier diabetes onset and overall higher incidence of diabetes 
(83).  This early-life treatment reduced the percentage of Treg and Th17 cells in lamina 
propria (LP), which may have contributed to the accelerated diabetes development.  In 
the Streptozotocin (STZ)-induced type 1 diabetes model, mice treated with antibiotics 
were fully protected from diabetes (84).  This was attributed to blocking pro-diabetic 
bacteria translocation to PLN (84).
Early-life treatment using vancomycin reduced the incidence of diabetes in one study 


























































different treatment protocols.  However, the protection in Hansen’s study was 
accompanied by an increase in the level of Akkermansia, which was later reported to be 
correlated with a pro-diabetic effect (85, 86).  A gluten-free diet can also reduce 
inflammation and diabetes incidence in NOD, with elevated abundance of Akkermansia.  
Adding gluten to the gluten-free diet reversed the protection, accompanied by a 
decreased level of Akkermansia (86).  More recently, a study showed that Akkermansia 
mediate glucose tolerance via IFN (87) using loss-and-gain-of-Akkermansia muciniphila 
approaches in IFN knock-out mice.  In a clinical study, a 4-day treatment with broad-
spectrum antibiotics (Vancomycin, Gentamicin and Meropenem) significantly shifted the 
gut microbiota composition but this did not have a clinical impact in respect of 
metabolic markers such as glucose tolerance or insulin secretion (88).  However, in a 
study by Endesfelder and coauthors a change of gut microbiota occurring as a result of 
dietary change had an impact on islet autoimmunity.  The authors stratified the 
children in the study based on the microbial communities identified.  They found that it 
was possible to detect functional associations between the diet consumed, the 
microbiome and development of autoimmunity.  They identified a subgroup of 
children where Bacteroides was dominant, with low Akkermansia in the gut microbiota 
and this was associated with early introduction of a non-milk diet, lower abundance of 
genes for the production of butyrate and early autoantibody development (89, 90).   
They postulated that low butyrate generation by the bacteria contributed to increased 


























































It is clear that the effect of gut microbiota on host immune responses early in life is 
much stronger than later in life.  This was observed in human studies demonstrating 
that the development of type 1 diabetes was closely related to gut microbiota, gut 
permeability and immune system in early-life.  Amarri and colleagues have previously 
found that gut bacteria and gut permeability as well as other immune markers were 
significantly altered in breast-fed infants (89).  Other early influences have been 
demonstrated in a Danish study where the authors found that antibiotics used in early-
life increased the incidence of type 1 diabetes in young children: however, this was also 
related to the mode of birth delivery, which has major effects on determining the 
composition of gut microbiota at the time of birth (91).  
Antibiotic treatment in adult mice is not as effective as prenatal or neonatal treatment 
in altering the course of type 1 diabetes.  However, later life antibiotic treatment can 
significantly alter the gut bacteria and it can have clear impact on diseases other than 
T1D, including Crohn’s disease (92), colitis (93), obesity and type 2 diabetes (94).  
In addition to antibiotics, it is known that innate immune system can also alter gut 
microbiota, which affect both type 1 and type 2 diabetes development (11, 30).  
However, it was not clear which type of bacteria contribute to the protection or 
promotion of diabetes.  Using a MyD88-deficient NOD mouse that has a defined T cell 


























































goodfellowii, in the gut can trigger diabetes development in islet-specific glucose-6-
phosphatase catalytic subunit-related protein (IGRP)-reactive CD8 T cell receptor NY8.3 
transgenic NOD model.  L. goodfellowii is a member of Fusobacteria, and expresses a 
protein peptide sharing a homologous sequence with IGRP and its abundance is 
correlated with the progression of diabetes (46).  This is the first evidence of molecular 
mimicry that relates to a bacterial antigen in initiation of diabetes onset, due to T cell 
cross-reactivity to the microbial peptide and leading to an activated autoimmune 
response.
5. Fecal microbiota transfer (FMT) as a potential therapy 
Gut bacterial composition may be altered by diet, antibiotics, probiotics, or by direct 
microbiota transfer.  Fecal microbiota transfer (FMT) has proven to be a effective way 
to transfer “healthy” microbiota, that may have beneficial effects on metabolism and 
the immune system in recipient mice (30, 95).  FMT has also been used in patients with 
colitis (96-98) and recently in cancer patients (99, 100).  We recently demonstrated 
that FMT could restore the gut microbiota and rebalance the gut hemeostasis, which in 
turns delayed diabetes onset in NOD mice (26, 29).  In other disease models, including 
obesity, the gut microbiota have been shown to contribute to generation of the 
metabolic syndrome (30).  FMT from lean mice to obese mice can ameliorate the 
metabolic syndrome in the obese mice due to the rebalancing of gut microbiota (101).  


























































The beneficial effects of FMT have been particularly used in patients suffering from 
Clostridium difficile infection (102, 103).  Although antibiotic treatment has been the 
mainstay of treatment of Clostridium difficile infection, some patients have developed 
recurrent infection later on and importantly antibiotic treatment for other medical 
conditions can lead to persistent infection with Clostridium difficile (104-106).  Since 
the clinical trial on FMT in patients with recurrent Clostridium difficile infection (103), 
considerable progress has been made in this field, including formulation of the 
microbiota and delivery route of the bacteria.  Oral administration is very common 
using capsules containing the gut microbiota of healthy donors after pathogen-free 
screening, stool purification and preservation processes (107).  In addition, FMT has 
also been effective in treating diseases like ulcerative colitis (108) and chronic pouchitis 
(109) in clinical practice.  Although FMT has not been used in T1D treatment, if specific 
combinations of beneficial bacteria could be identified, this could be a promising 
therapy, given that fecal filtrate has a similar efficacy to fecal microbiota in treating 
other medical conditions (110).  However, more comprehensive studies need to be 
performed to understand which what bacterium (or bacteria) and metabolites can 
trigger the imbalance of immune system at early-life in humans at high-risk of 
developing T1D. 
6. Perspectives and conclusion


























































modulate the immune system contributing to health or disease including T1D.  Birth 
delivery mode (cesarean section vs. vaginal delivery), breast vs. formulation feeding and 
antibiotic usage, all can have a strong impact on the health of newborn infants (111-
113).  The period in utero, as well as post-partum, is a crucial time for establishment of 
the immune system of the babies.  Intervention during early life may lead to novel and 
more effective therapeutic strategies in treating T1D.  There is no doubt that gut 
microbiota are associated with particular metabolites and can influence both metabolic 
pathways and the development of the immune system.  Many studies have shown that 
depletion or alteration of intestinal microbiota has a significant impact on gut mucosal 
and epithelial gene expression, as well as immune responses (114).  Gram-negative and 
Gram-positive bacteria can stimulate different immune responses and induce Th1 or Th2 
type cytokines, as well as proinflammatory or anti-inflammatory mediators (115-118).  
We summarized some of the bacteria studied in association with T1D (Table 1).    
APC dysfunction has been found to be associated with T1D development (119, 120), but 
previously this had not been correlated with alteration of gut bacteria.  Our recent 
studies provide evidence that tolerogenic APC are generated as the results of altered gut 
microbiota (25, 27).  Interestingly, the tolerogenic APCs can confer T1D protection and 
this protection can also be transferred to a second host and to the offspring.  
Probiotics and other strategies altering the gut microbiota, including FMT, could be a 


























































mucosal and systemic immune systems.  This “bug for drug” approach, also called 
“Bacteriotherapy” is being tested in different clinical trials for other medical conditions 
(121).  The prospect of this approach for T1D could be on the horizon.  Type 1 
diabetes has not only a genetically inherited component that determines susceptibility 
to disease, but the interaction with the environment to precipitate disease is a very 
important part of the pathogenesis.  Identifying modifiable environmental factors, such 
as the gut microbiota would provide a therapeutic target that could be modified by 
treatments that could be easy to administer.  It would be important to identify safe 
means of doing this that could potentially be administered very early in life.  Probiotics 
have already been tested in infants and young children but the appropriate composition 
should be identified.  Whether gut bacteria are involved in the initiation of the process 
leading to T1D or in the progression of -cell autoimmunity is still unclear (122).  A 
pure, culturable bacterial cocktail would need to be identified before this kind of 
regimen could be used in clinical practice.
A number of immunotherapeutic treatments have been trialed in human type 1 
diabetes, some of which have had a transient effect, but none as yet have been long-
lasting (123).  It has been argued that for a treatment to be successful, the innate 
immune system should present antigens in a tolerogenic manner to T regulatory cells 
(123) and this is potentially one of the ways in which altering the gut microbiota could 


























































be combined with others that could be synergistic in maintaining a tolerogenic 
environment.
In conclusion, both probiotic and antibiotic treatment can significantly alter the gut 
bacteria, as well as the bacteria composition in other sites of the body including the oral 
cavity.  The altered bacteria interact with the host immune system and reduce 
inflammatory cytokines as well as the expression of costimlatory molecules in APCs, 
inducing a tolerogenic environment.  However, further investigation is required and, in 
particular, more work done to identify less disease- promoting gut microbiota and how 
to maintain this type of gut microbiome. 
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Table 1: Summary of bacteria studied in association with T1D 
Bacteria Gram-positive 
or -negative










Lactobacillus johnsonii & L. 
reuteri
positive Healthy probiotics Protection 39, 81
Klebsiella pneumoniae negative Pathogen causing pneumonia Protection 41
Bifidobacterium positive Often as healthy probiotics Acceleration 67-69
Streptococcus positive Some pathogens, some commensal 
bacteria in mouth, skin, intestine and 
upper respiratory tract
Protection 40, 82
Akkermansia muciniphila negative Mucin-degrading, often anti-inflammatory 
effect
Protection 52, 90
Bacteroides negative processing complex molecules to simpler 
compounds in the host intestine
Acceleration 89, 90
Leptotrichia goodfellowii negative Oral commensal, pathogen in immune 
compromised patients
Acceleration in NY8.3 
NOD
46
